AC BioScience moves towards clinical trials

From its headquarters at the life sciences campus Biopôle, AC BioScience is pioneering the development of novel therapies in immune-oncology and tumour vascular normalization. Since 2017, the company has been identifying and developing molecules with a previous history of extensive and successful pre-clinical research.

AC BioScience has entered a partnership with Lexicon Pharmaceuticals, Inc., a biopharmaceutical company whose team identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Under the terms of this agreement, Lexicon grants a right-of-use of all its preclinical, CMC and clinical data for its proprietary drug LX3305 to AC BioScience for its oncology applications.

This agreement will permit AC Bioscience to seek approval from EMA to proceed directly to Phase 2 clinical trials. The medical objective is to validate and bring to clinical use, a novel approach to improve the treatment of metastatic pancreatic adenocarcinoma. Lexicon will receive an upfront payment and is eligible to receive milestone payments totalling up to $5.3 million.

AC BioScience has two additional drugs in development for fighting cancer. Thanks to the newly obtained CHF 0.8 million in a third seed round, the company is able to launch two clinical trials in 2021/2022. The bridge investment brings the company’s total seed investment to CHF 2.8 million.

(Press release/RAN)